slas 2022 News

GenSight Biologics to highlight gene therapies at Cell & Gene Meeting

By The Science Advisory Board staff writers
October 11, 2021

French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.

Dr. Magali Taiel, the company's chief medical officer, will present virtually during a prerecorded session on developments in the pipeline for the two therapies. Lumevoq is designed to treat vision loss caused by Leber hereditary optic neuropathy, while GS030 is for retinitis pigmentosa.

Optogenetic gene therapy provides hope for retinitis pigmentosa patients
Optogenetic therapy bypasses traditional methods of repairing defective photoreceptors in the eye by targeting other retinal cells. Recently, three examples...
Diamond Pharma, GenSight submit EMA application for ocular gene therapy
French biotechnology firm GenSight Biologics has submitted a marketing authorization application to the European Medicines Agency (EMA) for its ocular...

Copyright © 2021 scienceboard.net

Last Updated np 10/14/2021 4:02:21 PM